Swedish Orphan Drug Patent Portfolio
Swedish Orphan owns 1 orange book drug protected by 2 US patents Given below is the list of Swedish Orphan's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9301932 | Liquid pharmaceutical composition comprising nitisinone | 28 Feb, 2033 | Active |
| US5550165 | Pharmaceutical compositions for the treatment of hereditary tyosinemia type I | 27 Aug, 2013 | Expired |
Latest Legal Activities on Swedish Orphan's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Swedish Orphan.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 15 Sep, 2023 | US9301932 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 03 Sep, 2019 | US9301932 |
|
Recordation of Patent Grant Mailed
Critical
| 05 Apr, 2016 | US9301932 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 05 Apr, 2016 | US9301932 |
|
Email Notification
Critical
| 17 Mar, 2016 | US9301932 |
|
Issue Notification Mailed
Critical
| 16 Mar, 2016 | US9301932 |
| Dispatch to FDC | 02 Mar, 2016 | US9301932 |
|
Application Is Considered Ready for Issue
Critical
| 02 Mar, 2016 | US9301932 |
|
Issue Fee Payment Received
Critical
| 23 Feb, 2016 | US9301932 |
|
Issue Fee Payment Verified
Critical
| 23 Feb, 2016 | US9301932 |
|
Mail Notice of Allowance
Critical
| 12 Feb, 2016 | US9301932 |
|
Email Notification
Critical
| 12 Feb, 2016 | US9301932 |
|
Electronic Review
Critical
| 12 Feb, 2016 | US9301932 |
|
Notice of Allowance Data Verification Completed
Critical
| 09 Feb, 2016 | US9301932 |
|
Information Disclosure Statement considered
Critical
| 05 Feb, 2016 | US9301932 |
Swedish Orphan's Family Patents
Swedish Orphan drugs have patent protection in a total of 23 countries. It's US patent count contributes only to 11.5% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Swedish Orphan Drug List
Given below is the complete list of Swedish Orphan's drugs and the patents protecting them.
1. Orfadin
Orfadin is protected by 2 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9301932 | Liquid pharmaceutical composition comprising nitisinone |
28 Feb, 2033
(8 years from now)
| Active |
| US5550165 | Pharmaceutical compositions for the treatment of hereditary tyosinemia type I |
27 Aug, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Orfadin's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List